Surrozen, Inc. Common
SRZNSurrozen, Inc. is a biotechnology company focused on developing innovative therapeutics for autoimmune, inflammatory, and fibrotic diseases. It leverages its proprietary SUREkill platform to discover and develop antibody-based medicines aimed at modulating the immune system and improving patient outcomes.
Company News
Biotechnology company Surrozen reported a surprising Q2 2025 net income of $39.7 million, driven primarily by non-cash gains, while continuing to advance its ophthalmology pipeline focused on Wnt pathway modulation.
Surrozen Publishes Study in eLife Demonstrating the Promise of the SWEETS Platform, a Unique TPD Technology, to Further Enhance Wnt Signaling
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 at the 2024 European Association for the Study of the Liver (EASL) in Milan
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
Surrozen Presents Data Demonstrating the Promise of Antibody Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at ARVO 2024
